Clinical Trial Update: This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years [Phase 2]

View source ↗

Summary

A Phase 2 randomized study comparing two oral doses of INT131 (1 mg and 3 mg daily) versus placebo in treatment-naïve relapsing-remitting multiple sclerosis has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• INT131

Snippet

Sponsor: InteKrin Therapeutics, Inc. | Conditions: Multiple Sclerosis, Relapsing Remitting | Phase 2 | Status: COMPLETED